Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TAFASITAMAB for Diffuse large b-cell lymphoma refractory: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 40 adverse event reports in the FDA FAERS database where TAFASITAMAB was used for Diffuse large b-cell lymphoma refractory.

Most Reported Side Effects for TAFASITAMAB

Side Effect Reports % Deaths Hosp.
Disease progression 470 33.8% 239 54
Diffuse large b-cell lymphoma 346 24.9% 206 37
Off label use 203 14.6% 43 73
Death 146 10.5% 146 18
Neutropenia 99 7.1% 19 45
Covid-19 96 6.9% 33 57
General physical health deterioration 75 5.4% 33 33
Pneumonia 66 4.7% 28 45
Febrile neutropenia 64 4.6% 7 55
Drug ineffective 62 4.5% 40 5
Thrombocytopenia 60 4.3% 13 20
Lymphoma 57 4.1% 7 3
Malignant neoplasm progression 47 3.4% 17 12
Infection 42 3.0% 8 14
Diarrhoea 39 2.8% 5 14

Other Indications for TAFASITAMAB

Diffuse large b-cell lymphoma (930) Follicular lymphoma (113) Product used for unknown indication (86) Diffuse large b-cell lymphoma recurrent (37) Marginal zone lymphoma (24) Lymphoma (23) Non-hodgkin's lymphoma (22) B-cell lymphoma (18) High-grade b-cell lymphoma (17) Covid-19 (9)

Other Drugs Used for Diffuse large b-cell lymphoma refractory

RITUXIMAB (667) EPCORITAMAB-BYSP (353) AXICABTAGENE CILOLEUCEL (336) BENDAMUSTINE (283) CYCLOPHOSPHAMIDE (226) POLATUZUMAB VEDOTIN (223) ETOPOSIDE (165) POLATUZUMAB VEDOTIN-PIIQ (158) GEMCITABINE (147) LENALIDOMIDE (143)

Related Pages

TAFASITAMAB Full Profile All Diffuse large b-cell lymphoma refractory Drugs TAFASITAMAB Demographics TAFASITAMAB Timeline